SeaStar Medical HoldingICU -3.40%29 EBITDA Margin % is -709.49% as of Mar. 2026. GuruFocus rates ICU with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, SeaStar Medical Holding ranks worse than 77.75% on this metric.
SeaStar Medical Holding (NAS:ICU) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SeaStar Medical Holding EBITDA Margin % Related Terms
SeaStar Medical Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU vs MBRX, LEXX, INTI: EBITDA Margin % Comparison
For the Biotechnology subindustry, SeaStar Medical Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding (ICU) has a EBITDA Margin % of -709.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #734 out of 944 companies in the Biotechnology industry, placing it in the top 77.8%.
Is SeaStar Medical Holding's EBITDA Margin % too high?
SeaStar Medical Holding's current EBITDA Margin % is -709.49%. Based on the distribution chart, SeaStar Medical Holding ranks #734 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SeaStar Medical Holding has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's EBITDA Margin % compare to MBRX and LEXX?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #734 out of 944 companies for EBITDA Margin %. This places SeaStar Medical Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SeaStar Medical Holding and its competitors. SeaStar Medical Holding's current EBITDA Margin % is -709.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current EBITDA Margin % of -709.49%. The current EBITDA Margin % is -709.49%. SeaStar Medical Holding's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current EBITDA Margin % is -709.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
29GF Score
Get the complete analysis for ICU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICU has been successfully added to your 
